He is currently a PhD candidate at Rutgers University.
Visikol, founded by Johnson with partners Thomas Villani and Nick Crider, allows scientists to view tissue in 3D rather than the traditional 2D slide-based approach rendering tissues transparent -- adding significant value to fields like drug development and cancer diagnostics as it allows for more accurate information to be obtained from tissue.
The company recently launched Visikol® HISTO™, which requires no special equipment to clear tissue and provides a rapid, non-destructive, easy-to-use process that allows any researcher to add a new dimension to his or her research with the power of tissue clearing.
The technology is now being used by more than 160 researchers in the U.S. and Europe.
Visikol has raised $800,000 in venture capital and grants to advance its technology, including a $500,000 investment from Foundation Venture Capital Group, a $225,000 SBIR grant from the National Science Foundation and a recent $50,000 Innovation Corps Grant from the National Science Foundation.
"I'm incredibly honored to be recognized by Forbes for our accomplishments with Visikol. My co-founders and I look forward to moving our technology forward, improving clinical diagnostics," Johnson said.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/visikol-co-founder-michael-johnson-named-to-2017-forbes-30-under-30-list-300389378.html
SOURCE Foundation Venture Capital Group, LLC